AnaptysBio, Inc. (ANAB) News

AnaptysBio, Inc. (ANAB): $19.19

-0.79 (-3.95%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ANAB to Watchlist
Sign Up

Industry: Biotech


Ranked

of 393

in industry

Filter ANAB News Items

ANAB News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ANAB News Highlights

  • For ANAB, its 30 day story count is now at 4.
  • Over the past 27 days, the trend for ANAB's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about ANAB are BDSI and BEAT.

Latest ANAB News From Around the Web

Below are the latest news stories about Anaptysbio Inc that investors may wish to consider to help them evaluate ANAB as an investment opportunity.

AnaptysBio, Inc. (ANAB) Earnings Expected to Grow: What to Know Ahead of Q4 Release

AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

Amgen''s (AMGN) KRAS Inhibitor Gets Nod in Japan for Lung Cancer | Investing.com

Stocks Analysis by Zacks Investment Research covering: Amgen Inc, Dynavax Technologies Corporation, Mirati Ther, AnaptysBio Inc. Read Zacks Investment Research''s latest article on Investing.com

Investing.com | January 21, 2022

BioDelivery (BDSI) Stock Up on Raised Guidance for 2021

BioDelivery Sciences International (BDSI) raises its financial guidance for full-year 2021. BDSI expects sales at the high end of its previous guidance.

Yahoo | January 21, 2022

Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug

Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.

Yahoo | January 19, 2022

AnaptysBio, Inc. (ANAB): Hedge Funds Are Snapping Up

Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don''t make them change their opinion towards a

Insider Monkey | January 12, 2022

AnaptysBio, Inc.'s (NASDAQ:ANAB) Intrinsic Value Is Potentially 23% Below Its Share Price

How far off is AnaptysBio, Inc. ( NASDAQ:ANAB ) from its intrinsic value? Using the most recent financial data, we'll...

Yahoo | January 8, 2022

Recludix Pharma Announces Scientific Advisory Board

SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the establishment of its scientific advisory board. “We are thrilled to have established a group of distinguished scientific thought leaders as advisors to the company,” said Nancy Whiting, Pharm.D., chief executive officer of Recludix. “Our scientific advisory board consists of pioneers in precision medicine

Yahoo | January 6, 2022

AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present an overview of AnaptysBio as part of the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 from 8:15 8:55 a.m. ET.

GlobeNewswire | January 5, 2022

Anaptysbio Inc (ANAB) President, CEO Hamza Suria Sold $1.3 million of Shares

President, CEO of Anaptysbio Inc (30-Year Financial, Insider Trades) Hamza Suria (insider trades) sold 36,645 shares of ANAB on 12/20/2021 at an average price of $35.57 a share.

Yahoo | December 23, 2021

AnaptysBio, Inc. (NASDAQ:ANAB) Shares Purchased by Invesco Ltd.

Invesco Ltd. boosted its stake in AnaptysBio, Inc. (NASDAQ:ANAB) by 7.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,083 shares of the biotechnology company’s stock after acquiring an additional 1,330 shares during the period. Invesco Ltd. owned 0.07% of […] The post AnaptysBio, Inc. (NASDAQ:ANAB) Shares Purchased by Invesco Ltd. appeared first on ETF Daily News .

ETF Daily News | December 14, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5503 seconds.